Search

Find exactly what you’re looking for.

Showing 1-7 of 7 results

Welcome to Saul Ewing’s Public Companies Quarterly Update series. Our intent is to, on a quarterly basis, highlight important legal developments of which we think public companies should be aware. This edition is related to developments during the first quarter of 2024. If you would like to discuss...

Welcome to Saul Ewing’s Public Companies Quarterly Update series. Our intent is to, on a quarterly basis, highlight important legal developments of which we think public companies should be aware. This edition is related to developments during the fourth quarter of 2023. If you would like to discuss...

The FTC has announced the annual updates to the Hart-Scott-Rodino (“HSR”) size thresholds, fees and the daily penalty for HSR violations. The updated thresholds and fees were published in the Federal Register on January 26, 2023 and will take effect on February 27, 2023. See Federal Register...

BACKGROUND: The Rule - What It Means and What It Prohibits A somewhat little-known and obscure provision of U.S. antitrust law – Section 8 of the Clayton Act – makes it illegal in certain circumstances for the same person to serve as a director of competing corporations. If certain conditions exist...

LATEST UPDATE The FTC has voted to extend the public comment period on its proposed rule to ban employers from imposing non-competes on their workers, and will now be accepting comments on the proposed rule until April 19, 2023. Comments can still be submitted in either writing or online using the...

Saul Ewing LLP, a full-service law firm with attorneys in 16 offices, today announced that 59 attorneys from the Firm received the distinguished honor of being recognized for legal excellence and client service by Chambers USA 2022. Several of the Firm’s practice areas also earned high rankings...

Washington, D.C., November 24, 2021 – Saul Ewing LLP served as counsel to Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the successful completion today of its previously announced $450 million acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The acquisition strengthens Supernus'...

For More Information